Europe

PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. This report focuses on the results from a market assessment on Shigella vaccines for use in traveler and military populations. It aims to provide a better understanding of the size and specific segments of these markets, as well as an evaluation of the factors that may impact demand and utilization of these vaccines. The traveler and military markets are but one segment of a larger global Shigella vaccine market which has enormous potential to impact global health among children and adults in low- and middle-income countries.

Respiratory syncytial virus (RSV) is a major, under-recognized public health problem causing more severe respiratory infections and hospitalizations in infants and young children each year than any other pathogen—with no widely available interventions to prevent it. Now, promising new tools for early RSV disease prevention are close on the horizon and the chance to address this pervasive virus has never been better.To raise awareness, PATH and the World Health Organization are developing an evolving toolkit of communications materials that public health stakeholders and advocates can use to share information about RSV disease, forthcoming prevention tools, and delivery considerations. To learn more about the toolkit, visit the web page.Editable files are available upon request. Please contact us.

PATH implements innovative tuberculosis (TB) prevention, diagnosis, and care while responding to the pressing needs of humanitarian response.

During the Union World Conference on Lung Health 2022, PATH will showcase our continued commitment to advancing TB care through patient-centered innovations and systems-level advancements.

This fact sheet describes Chemistry, Manufacturing, and Controls (CMC) work at PATH. It covers what CMC is and why it's important, where we work, our capabilities, and how interested parties can reach out to us for collaboration opportunities.

This year’s annual report features our annual financial overview, a list of PATH’s funders and supporters, and our accomplishments in 2021.

Medical oxygen proved to be a lifesaving drug during the COVID-19 pandemic in the absence of a proven therapeutic solution for patients suffering from the infection. In May 2021, India's health infrastructure was overwhelmed by the caseload, with a lack of oxygen, manpower, drugs, and hospital beds. The most difficult challenge for the country was providing an adequate volume of medical oxygen for the most severely ill patients who were unable to breathe on their own.PATH, with its extensive experience in respiratory care management, responded quickly and played a critical role in strengthening the oxygen ecosystem at this critical juncture. It provided technical assistance in the installation and procurement of PSA oxygen generation plants and oxygen concentrators, as well as improved their readiness.Furthermore, in order to build capacity for long-term sustainability, PATH developed, translated, and disseminated high-quality, reliable, and ready-reference knowledge products, such as the Guidebook on Medical Oxygen Management, Oxygen Posters, Standard Operating Procedures, Checklists, Case Studies, and Success Stories on various aspects of the oxygen ecosystem.

This document provides the benchmarks self-assessments, examples and resources to implement PATH's four change strategies through our projects and proposals.

Use these slide decks to share the evidence supporting a single-dose regimen of HPV vaccine. Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.